Alembic Pharmaceuticals Ltd. Stock Falls to 52-Week Low of Rs.665.1

Recent Price Movement and Market Context

The stock has been on a downward trajectory for the past five trading sessions, losing 6.62% over this period. Today's closing price of Rs.665.1 represents the lowest level the stock has traded at in the last year, well below its 52-week high of Rs.1107.8. This decline contrasts with the broader market trend, as the Sensex advanced by 0.75% today, closing at 76,070.84 points after opening 323.83 points higher. Despite the Sensex's positive momentum, Alembic Pharmaceuticals underperformed its sector by 1.48% and is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained bearish sentiment.

Financial Performance and Valuation Metrics

Over the past year, Alembic Pharmaceuticals has delivered a total return of -18.82%, significantly lagging behind the Sensex's 2.56% gain. The company’s long-term growth has been subdued, with operating profit declining at an annualised rate of 8.78% over the last five years. The most recent quarterly earnings per share (EPS) stood at Rs.6.77, marking the lowest in recent periods. Additionally, the inventory turnover ratio for the half-year is at a low 2.79 times, while the debt-to-equity ratio has increased to 0.28 times, the highest level recorded in the same period.

Technical Indicators Reflect Bearish Trends

Technical analysis further underscores the stock’s weak momentum. The Moving Average Convergence Divergence (MACD) indicator is bearish on both weekly and monthly charts. Bollinger Bands also signal bearishness across these timeframes. The KST (Know Sure Thing) indicator and Dow Theory assessments are mildly bearish on weekly and monthly scales. The Relative Strength Index (RSI) shows no clear signal, while the On-Balance Volume (OBV) indicates no trend weekly and a mildly bearish pattern monthly. Collectively, these technical signals align with the stock’s recent price declines and suggest continued pressure.

Comparative Performance and Market Position

In addition to underperforming the Sensex, Alembic Pharmaceuticals has lagged behind the BSE500 index over the last three years, one year, and three months. The stock’s Mojo Score currently stands at 37.0, with a Mojo Grade of Sell, downgraded from Hold on 25 Nov 2025. The company is classified as a small-cap within the Pharmaceuticals & Biotechnology sector, which has seen mixed performance in recent months. Despite the broader market’s upward movement, Alembic’s share price has not reflected this trend, indicating sector-specific or company-specific pressures.

Balance Sheet and Debt Servicing Capacity

On a positive note, Alembic Pharmaceuticals maintains a relatively low debt burden, with a Debt to EBITDA ratio of 0.90 times, suggesting a strong ability to service its debt obligations. The company’s Return on Capital Employed (ROCE) is 12.6%, which is considered attractive within its sector. Furthermore, the enterprise value to capital employed ratio stands at 2.2, indicating the stock is trading at a discount relative to its peers’ historical valuations. These factors provide some cushion amid the stock’s price weakness.

Profitability and Growth Metrics

While the stock price has declined, the company’s profits have increased by 11.7% over the past year. The Price/Earnings to Growth (PEG) ratio is 1.7, reflecting moderate valuation relative to earnings growth. Institutional investors hold a significant 20.41% stake in Alembic Pharmaceuticals, which may reflect confidence in the company’s fundamentals despite recent price declines. However, the stock’s recent performance and technical indicators suggest that these positive fundamentals have yet to translate into upward price momentum.

Summary of Key Concerns

The stock’s decline to Rs.665.1 reflects a combination of factors including sustained negative returns over the past year, underperformance relative to benchmark indices, and technical indicators signalling bearish momentum. The company’s operating profit has contracted over the last five years, and recent EPS figures remain subdued. Inventory turnover and debt levels have also raised some cautionary signals. Despite these challenges, the company’s ability to service debt and attractive valuation metrics provide some balance to the overall picture.

Market Environment and Sector Dynamics

The Pharmaceuticals & Biotechnology sector has experienced varied performance, with some large-cap stocks leading gains in the broader market. Alembic Pharmaceuticals, as a small-cap entity, has not mirrored this trend, reflecting sector-specific pressures or company-level factors. The Sensex’s current position below its 50-day moving average, with the 50 DMA below the 200 DMA, indicates a cautious market environment that may be influencing investor sentiment towards stocks like Alembic.

Conclusion

Alembic Pharmaceuticals Ltd.’s stock reaching a 52-week low of Rs.665.1 marks a notable point in its recent trading history. The stock’s performance over the past year and technical indicators suggest ongoing challenges in regaining upward momentum. While certain financial metrics and institutional holdings provide some stability, the overall trend remains subdued as reflected in the company’s downgraded Mojo Grade and relative underperformance. Investors and market participants will continue to monitor the stock’s price action in the context of sector and market developments.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →